OTCPicks.com: OTCPicks.com Stocks to Watch for Monday, July 28th EPCT, PILL, INBP, POWN

Jul 28, 2008 (M2 PRESSWIRE via COMTEX) -- PILLE | Quote | Chart | News | PowerRating -- Our Stocks to Watch tomorrow include EpiCept Corp. (Nasdaq: EPCT), ProxyMed Inc./MedAvant Healthcare Solutions Inc. (Nasdaq: PILL), Integrated BioPharma Inc. (Nasdaq: INBP), POW! Entertainment Inc. (OTC: POWN)

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

EPICEPT CORPORATION (NASDAQ: EPCT | Quote | Chart | News | PowerRating) "Up 170.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/EPCT.php

EpiCept Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. The company's lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia. Its cancer product portfolio includes Azixa, a Phase II clinical trial product to treat the patients with primary glioblastoma and melanoma that has metastasized to the brain and non-small-cell lung cancer that has spread to the brain; and EPC2407, a Phase I clinical trial completed oncology product candidate for the treatment of patients with advanced solid tumors and lymphomas. The company's pain product portfolio comprises EpiCept NP-1, a prescription topical analgesic cream for the long-term relief of peripheral neuropathies; LidoPAIN BP, a prescription analgesic non-sterile patch to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; and LidoPAIN SP, a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound. It has strategic alliances with Endo Pharmaceuticals, Inc.; Myriad Genetics, Inc.; DURECT Corporation; Adolor Corporation; Epitome Pharmaceuticals Limited; and Shire Biochem, Inc. The company was founded in 1993 and is based in Tarrytown, New York.

EPCT News:

July 25 - Ceplene Receives Positive European Opinion for Approval From CHMP

* Marketing Authorization Normally Anticipated within 67 Days in the EU

* Conference Call to be Held July 28 at 9:00 a.m. Eastern Time

EpiCept Corporation (Nasdaq: EPCT | Quote | Chart | News | PowerRating) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). This positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by the CHMP. Ceplene has been designated as an orphan medicinal product, and as such is entitled to 10 years of marketing exclusivity in the EU.

EpiCept attended an oral explanation hearing at the CHMP's plenary meeting on July 22, 2008. Following this oral explanation, the CHMP recommended that Ceplene be granted a full marketing authorization under the provision of Exceptional Circumstances.

As part of granting of the marketing authorization under Exceptional Circumstances, EpiCept has agreed to perform two post-approval clinical studies. One of the studies seeks to further elucidate the clinical pharmacology of Ceplene by assessing certain biomarkers in AML patients in first remission. The other study will assess the effect of Ceplene/IL-2 on the development of minimal residual disease in the same patient population. EpiCept is entitled to seek further guidance on the design of such studies from the EMEA through the protocol assistance procedure.

"We are thrilled with the positive opinion reached by the CHMP and are pleased by the overwhelming support for Ceplene we received from key opinion leaders in hematology across Europe during this successful re-examination effort," stated Jack Talley, President and CEO of EpiCept. "Ceplene, in conjunction with IL-2, is the first therapy shown to significantly prolong leukemia-free survival and prevent relapse in AML patients in first remission."

The CHMP's recommendation will now be forwarded to the European Commission for issuing a marketing authorization in the form of a Commission Decision, which normally occurs within 67 days. The marketing authorization with unified clinical usage for Ceplene granted under the Centralized Procedure will be valid for the entire European Union as well as in Iceland, Liechtenstein and Norway.

"We are highly optimistic about the commercial prospects for Ceplene and we intend to pursue its commercial introduction as expeditiously as possible," continued Mr. Talley. "We are evaluating all of our strategic options for the marketing of Ceplene, and will continue to work towards realizing the drug's potential to fulfill an important unmet medical need for AML patients in Europe."

Conference Call

EpiCept announced that it will host a conference call to discuss this opinion and the Ceplene program on Monday, July 28, 2008 at 9:00 a.m. Eastern Daylight Time.

To listen to the conference call, please dial:

(877) 494-5472 (United States and Canada) (706) 758-9407 (International) The access code for the call is 57724791

A web cast of the conference can be accessed at www.epicept.com. The webcast will be archived for 90 days.

A playback of the call will be available for one week and may be accessed by dialing:

(800) 642-1687 (United States and Canada) (706) 645-9291 (International) Please reference reservation number 57724791

ABOUT ACUTE MYELOID LEUKEMIA (AML)

AML is the most common type of leukemia in adults. There are approximately 40,000 AML patients in the EU, with 16,000 new cases occurring each year. Once diagnosed with AML, patients are typically treated with induction chemotherapy and consolidation therapy, with the majority achieving complete remission. However, about 75-80% of patients who achieve first remission will relapse, with the median time in remission before relapse being only 12 months with current treatments. Less than 5% of relapsed patients survive long term.

ABOUT CEPLENE

Ceplene is EpiCept's compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

PROXYMED INCORPORATED (NASDAQ: PILL | Quote | Chart | News | PowerRating) "Up 37.50% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/PILL.php

ProxyMed, Inc., doing business as MedAvant Healthcare Solutions, is an information technology company that facilitates the exchange of medical claim and clinical information among doctors, hospitals, medical laboratories, and insurance payers. It connects payers with providers in a real-time environment for the purpose of transparently messaging administrative, financial, and clinical information. The company offers products and services to process healthcare transactions, including claims, ERA, eligibility, claims status, referral authorization, and encounters. Its claims processing services include real-time processing; myMedAvant, a real-time Web portal; electronic attachments to claims possible; "Front door" pre-adjudication services; and same session claims processing. ProxyMed has strategic partnership with Bloodhound and The Sentinel Group. The company was founded in 1987 and is headquartered in Norcross, Georgia.

PILL News:

July 24 - MedAvant Wins Interim Approval From Bankruptcy Court for $2.9 Million in New Financing to Support Ordinary Course of Business in Chapter 11

Court Also Approves Motions to Pay Employees, Rebates and Critical Vendors

MedAvant Healthcare Solutions (Nasdaq: PILL | Quote | Chart | News | PowerRating) (MedAvant), a leader in healthcare technology and transaction services, announced that the United States Bankruptcy Court Judge presiding over its chapter 11 case in Delaware approved all of the initial motions presented at its first hearings important to the continued normal operations of the Company. Among the motions approved by the Court on an interim basis include the debtor-in-possession financing commitment of $2.9 million in new liquidity by its senior lender Laurus Master Fund, Ltd. This was done to support the Company's business operations during the chapter 11 case. In addition, the Court approved the Company's motion to pay employee wages/benefits, honor its customer rebate programs - both pre-petition balances and post-petition accruals - and to pay certain critical vendors.

"We are very pleased with the Court's rulings today and believe that they are important steps forward in our ongoing efforts to build a new, stronger company," said Peter Fleming, MedAvant interim Chief Executive Officer. "With the approval of all of our motions for new financing and to continue normal operations, our employees, our partners, and our customers will see nothing but a positive difference in our day-to-day business. We believe the judge's approval underscores the fundamental soundness of our restructuring strategies."

The Company filed for chapter 11 protection on July 23 in order to address its debt burdens through a sale and restructuring process. As previously announced, the Company has agreed to sell substantially all its business to Marlin Equity Partners, subject to higher and better bids at an auction to be conducted under section 363 of the Bankruptcy Code. The Bankruptcy Court will hear the Company's motion for approval of the bid procedures (including the setting of the bid and auction schedule) on August 4. The Company is requesting that initial bids be submitted by September 2 and that the auction itself be held on September 3 at the offices of its Delaware bankruptcy counsel Young, Conaway, Stargatt & Taylor. The Company's lead bankruptcy counsel, Michael P. Richman, of Foley & Lardner LLP in New York, told the Court today that the Company expects there to be competitive bidding based upon expressions of interest received from a number of parties both before and since the chapter 11 filing.

ABOUT MEDAVANT HEALTHCARE SOLUTIONS

MedAvant is a national connectivity network that connects payers with providers in a real-time environment for the purpose of transparently messaging administrative, financial and clinical information in order to lower total administrative costs, improve payer, provider and member relationships, and to ultimately improve clinical outcomes.

For more information, visit www.medavanthealth.com. MedAvant is a trade name of ProxyMed, Inc.

INTEGRATED BIOPHARMA INCORPORATED (NASDAQ: INBP | Quote | Chart | News | PowerRating) "Up 31.56% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/INBP.php

Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its core nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. Through its subsidiary, AgroLabs, Inc., INBP distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Naturally Superberry Upgrade and among various other nutritional products. Additionally, through its subsidiary, InB:Manhattan Drug Company, INBP manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized healthcare providers. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.ibiopharma.com.

INBP News:

July 25 - Integrated BioPharma, Inc. Announces Spin-Off of iBioPharma, Inc. (Formerly InB: Biotechnologies, Inc.)

Integrated BioPharma, Inc. (Nasdaq: INBP | Quote | Chart | News | PowerRating) announced that it has established a record date and a distribution date with respect to the spin-off of the Company's interest in iBioPharma, Inc. (formerly InB:Biotechnologies, Inc.) ("iBioPharma"), pro rata to all of INBP's public stockholders (the "Spin-Off"). INBP has responded to all comments made by the U.S. Securities and Exchange Commission ("SEC") to the Company's Information Statement and Form 10 relating to the Spin-Off and has been notified by the SEC that there will be no further comments.

The shares will be distributed, in book-entry form, effective as of 11:59 p.m. on August 8, 2008 (the "Distribution Date"). For each share of the Company's common stock that a stockholder owns as of the end of August 4, 2008 (the "Record Date"), such stockholder is entitled to receive one share of iBioPharma's common stock. However, any holder of the Company's stock who sells shares of the Company's stock after the Record Date but before the date NASDAQ sets as the "ex distribution" date, which we expect will be the next business day after the Distribution Date or a few days thereafter, depending on when a market for iBioPharma develops, will also be selling his, her or its entitlement to receive shares of iBioPharma common stock in the Spin-Off, pursuant to what is referred to by NASDAQ as a "due bill." Investors are encouraged to consult with their financial advisors regarding the specific implications of selling the Company stock before the Distribution Date or the "ex distribution" date.

It is expected that shares of iBioPharma's common stock will begin trading on the OTC Bulletin Board under the symbol "IBIO" on August 8, 2008 or shortly thereafter.

E. Gerald Kay, Chairman and CEO of the Company, stated, "We are pleased to complete our previously announced strategic plan to spin-off our Biotechnologies segment. We strongly believe in the long-term value of the propriety intellectual property developed and owned by iBioPharma, particularly in the growing area of vaccines and therapeutic proteins. We also believe that iBioPharma will be able to raise capital and form necessary affiliations with other companies more effectively as a stand-alone company than as our subsidiary. The effect of the Spin-Off on INBP will be to terminate further use of cash flow to fund further iBioPharma research, development and implementation, which is accounted for as expenses and which have been reflected as operating losses of the Company." Mr. Kay further stated, "The Company continues to believe that the Spin-Off is very much in the interest of our shareholders who will retain their shares of the Company and receive a proportionate interest in the equity of iBioPharma as a dividend."

POW! ENTERTAINMENT (OTC: POWN | Quote | Chart | News | PowerRating) "Up 15.38% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/POWN.php POW! (Purveyors of Wonder) Entertainment, Inc., an advanced media and entertainment company with a first-look deal with Disney, was founded by world-famous comic book and motion picture icon Stan Lee, together with award-winning producer Gill Champion and intellectual property specialist Arthur Lieberman, Esq. POW!'s principals have extensive backgrounds in the entertainment industry encompassing the creation, production and licensing of original intellectual properties, including some of the most successful entertainment franchises of all time. POW!, capitalizing on this combined expertise, specializes in franchises for the entertainment industry, including animation and live-action feature films, plus television, DVDs, video games, merchandising and related ancillary markets, all of which contribute to global expansion. POW! partners with other individuals and entities of entertainment's top echelon, including studios and networks, in the creation, licensing and distribution of new POW! character franchises.

POWN News:

July 25 - Walt Disney Studios Home Entertainment and Stan Lee's POW! Entertainment Team Up For a Groundbreaking Event in Comic Book History

The Walt Disney Studios Announced an Extension to Stan Lee's POW Entertainment, Inc. Deal

Stan Lee, visionary co-creator of Spider-Man, X-Men, Iron Man, The Hulk, Daredevil and the Fantastic Four, is teaming up with Walt Disney Studios Home Entertainment (WDSHE) to introduce a revolutionary new concept in original superheroes and the comic book format: Time Jumper, which will become the industry's most ambitious digital comic book series ever designed to release on multiple platforms. In addition to the Time Jumper' initiative, The Walt Disney Studios announced an extension of Stan Lee's POW Entertainment, Inc production deal that covers all forms of media from movies and television through to publishing, games, the Internet and mobile-Web.

POW! Entertainment, Inc. (OTC: POWN), Stan Lee's media production company, in partnership with WDSHE is developing the central arc of the story and mythology of Time Jumper. In tandem, Disney Interactive Media Group's Disney Online and Disney Publishing Worldwide will be working collaboratively to develop their own made-for-medium content using the mythology across Web, mobile and a host of publishing platforms, and help augment digital distribution opportunities which will ensure an overall enhanced consumer experience.

Time Jumper is being written and developed to offer a dynamic opportunity for consumers to engage in a multi-dimensional narrative adapted specifically for various platforms, to maximize their experience and interaction with the characters and their universe trans-media. Consumers will have the accessibility to download single or multiple episodes onto a media platform of their choice anytime, anywhere, as well as purchase the comic book in print. The new digital comic book format combines the traditional print look and feel, including dialogue and thought bubbles, with today's cutting edge multimedia elements, including edgy visuals, music, voices and a fast-paced storyboard, to take a classic genre into the next dimension.

Stan Lee said, "I am honored to be in association with Disney, not only through the extension of our original deal, but also in breaking ground by creating a new superhero, that is destined to bring his own brand of thrills and adventure to so many varied forms of story telling as only Disney can provide them." Lee continued, "Our Time Jumper' is more than a typical superhero. He's a trend-setting breakthrough across all media; a hero for today's digital age and tomorrow's multiplatform entertainment."

"This is an exciting project for everyone involved, and our aim is to deliver great content, that will enrich and deepen the consumers experience," commented Bob Chapek, Walt Disney Studios Home Entertainment Worldwide President. "We feel that the dynamic delivery of this important Studio initiative, coupled with the fact that we are working in collaboration with such a master storyteller as Stan Lee, will make this an electrifying product."

"Time Jumper' is a natural fit for interactive media and we're thrilled to be working with such a creative visionary to help bring the story to life through multiple digital platforms including the Internet and mobile Web," stated Paul Yanover, executive vice president and general manager, Disney Online. "Our focus is to not only help deliver the story, but become an interactive part of telling the story of Time Jumper.'"

"Disney Publishing Worldwide is thrilled to give kids an incredibly unique reading experience through Time Jumper,'" said Russell Hampton, president, DPW. "We are very proud to add Stan Lee's comics and graphic novels in both print and digital formats to our rich heritage of storytelling."

ABOUT TIME JUMPER

Terry Dixon, the greatest agent of the secret government organization known as HUNT (Heroes United, Noble and True), has a cell phone like no other. Invented by Terry's father, it's called The Articulus and it has all the latest and greatest cell phone features - plus one: it's also a time machine!

Ever mindful of the dangers of Articulus falling into the wrong hands, Terry's father ensured that it can be operated by only two people on earth - Terry and his brother Sam. But Sam, the original Time Jumper, has been lost in time, forcing Terry, an unlikely hero, to step into his shoes. As Terry's search for his brother propels him through space and time, he is pursued by Charity Vyle, the beautiful, diabolical head of a worldwide criminal cartel called CULT (Council of Unlawful, Loathsome Terrorists), who wants Articulus for her own nefarious schemes. Each episode, Terry tries to stay one step ahead of his sworn enemy, while tracking down new clues to Sam's whereabouts.

ABOUT WALT DISNEY STUDIOS HOME ENTERTAINMENT

Walt Disney Studios Home Entertainment, a recognized leader in the home entertainment industry, is the marketing, sales and distribution company for Walt Disney, Touchstone, Hollywood Pictures, Miramax and Buena Vista product, which includes DVD, Blu-ray Disc and electronic distribution. Walt Disney Studios Home Entertainment is a division of The Walt Disney Studios.

ABOUT DISNEY PUBLISHING WORLDWIDE

Disney Publishing Worldwide (DPW) is the world's largest publisher of children's books and magazines, with over 400 children's magazines published and 120 million children's books sold each year. Disney Book Group (DBG) and Disney Global Magazines, part of DPW, publish books and magazines via both vertical publishing structures and through licensees around the world. DBG's vertical imprints include Disney Editions, Disney-Hyperion Books, Disney-Jump at the Sun and Disney Press as well as Disney Libri in Italy. Headquartered in White Plains, NY and Milan, Italy, Disney Publishing Worldwide publishes books and magazines in 85 languages in 75 countries, reaching more than 100 million readers each month.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index